CD19-CAR-T Cells in Patients With R/R B-ALL

PHASE1UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 20, 2018

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
B-cell Acute Lymphoblastic Leukemia
Interventions
BIOLOGICAL

CD19-CAR-T Cells

T cells purified from the PBMC of subjects or subjects' relatives which depends on their conditions, transduced with 4-1BB/CD3-ζ lentiviral vector, expanded in vitro for future administration.

Trial Locations (1)

065000

RECRUITING

Hebei Yanda Ludaopei Hospital, Langfang

Sponsors
All Listed Sponsors
lead

Bioceltech Therapeutics, Ltd.

INDUSTRY